Skip to main content
. 2021 Aug 1;60(15):2367–2374. doi: 10.2169/internalmedicine.6127-20

Figure 1.

Figure 1.

Bar graphs of the relative changes in the E/e’ from baseline to six months after the administration of dapagliflozin, showing that these changes in the E/e’ in patients with dyslipidemia tended to be larger than in patients without dyslipidemia, although without statistically significant difference.